Wells Fargo raised the firm’s price target on Ascendis Pharma (ASND) to $322 from $297 and keeps an Overweight rating on the shares. The firm believes shares should trade up about 10% as the 52-week COACH data resets the bar higher in achondroplasia, with the combo likely to drive higher market share for TransCon CNP. Wells’ estimates move up, and the TransCon CNP+Skytrofa combo is likely to become the standard of care over time.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Posts Strong Year-Long Phase 2 COACH Data for TransCon CNP and hGH Combo in Achondroplasia
- Ascendis Pharma: Advancing Achondroplasia Combo Franchise and De-Risked Regulatory Path Support Buy Rating and $242 Target
- Ascendis Pharma announces topline results from Week 52 of COACH trial
- Ascendis Pharma Advances Weekly Skytrofa Trial in Pediatric Growth Disorders: What Investors Should Watch
- TD Cowen Analyst Highlights Ascendis Pharma as Priority Healthcare Name With Buy Rating and Expected Outperformance